Department of Surgery
Andrew N. De la Torre, M.D.
Clinical InfoMedical Expertise
1) Liver, Pancreas & Bile duct Surgery (Minimal access, Laparoscopic & open) 2) Clinical trials in cancers of the liver and pancreas.
University Hospital, Newark
St. Michael's Medical Center - Newark
Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.
- Aetna, Inc.
- Devon Health Services/ULLICO
- FedMed, Inc
- Horizon BCBS Managed Care
- Horizon NJ Health
- Oxford Health Plans
- Prime Health Services, Inc.
- Qual Care HMO
- Qual Care PPO
- Three Rivers Provider Network
- United Health Care Corp
- United Healthcare Community Plan (formerly AmeriChoice of NJ, Inc.)
Johns Hopkins School of Medicine
Class of 1989
Queens College, CUNY
Flushing, New York
Class of 1984
New Jersey Medical School
Newark, New Jersey
Kidney and Pancreas transplant
University of Maryland Medical Systems
New Jersey Medical School
Newark, New Jersey
M.D., 1989, Johns Hopkins University School of Medicine
Licensure & Certification
|Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon S, Marotta P, Vierling J, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b Dose-Ranging Study of PEG- Interferon-Lambda Plus Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Hepatology. 2010 May 14|
|Abushahba W, Lasfar A , Balan M, Castaneda I, Yuan Y, Prescott L, Reuhl K, Raveche E, de la Torre AN, Kotenko SV. Antitumor Activity of Type I and Type III Interferons in BNL Hepatoma Model. Cancer Immunol Immunother. 2010 Mar 9|
|Ferrante JM, Winston DG, Chen PH, de la Torre AD Family Physicians’ Knowledge and Practices Regarding Chronic Hepatitis and Monitoring for Liver Cancer. Family Medicine Family Medicine 2008 May: 40(5), 345-351|
|Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, Wachsberg RH, de la Torre AN, Debroy M, Fisher A, Wilson DJ, Samanta AK. The ischemic preconditioningparadox in deceased donor liver transplantation-evidence from a prospectiverandomized single blind clinical trial. Am J Transplant. 2007 Dec;7(12):2788-96.|
|Abujudeh H, Contractor D, delaTorre A, Koneru B. Rescue TIPS in acute Budd-Chiari syndrome. AJR Am J Roentgenol. 2005 Jul;185(1):89-91|
|Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ, de la Torre AN. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2005 Feb;27(2):192-8|
|Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005 Feb;11(2):196-202|
|Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, dela Torre A, Samanta A, Korogodsky M. Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg. 2004 Sep;139(9):992-6|
|Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl. 2004 Feb;10(2):193-8|
|16. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, dela Torre AN, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for Hepatocellular carcinoma. J Am Coll Surg J Am Coll Surg. 2003 Nov; 197(5): 759-64|
Areas of Interest
Immunotherapy Against Cancers in the Liver
My work focuses on immune stimulation to fight primary and metastatic cancers in the liver. There are 2 main protocols. The first (clinicaltrials.gov Protocol ID NCT00553683) uses autologous prime-boost anti-tumor vaccination in patients with hepatomas or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver. This is a phase I/IIa clinical trial using 1) low dose cyclophosphamide to reduce tumor driven immune tolerance, 2) low dose radiation to the tumor, to increase expression of tumor antigens, 3) injection of an immune stimulant, TLR III agonist Poly IC:LC, into and around the tumor to activate the body’s immune defenses, and 4) tumor ablation to reduce production of tumor promoting and immunosuppressive factors. This is referred to as “Priming”. Patients are then subject to systemic administration of POLY ICLC to “Boost” the anti-tumor immune response. The second (clinicaltrials.gov Protocol ID NCT01387555) uses an oncolytic poxvirus, or vaccinia virus (JX-594) that are highly selective to attack cancers and have minimal side effects, limited to flu-like symptoms. The (JX-594 strain backbone of has been used safely in millions of people as part of a worldwide vaccination program. Features include 1) rapid and motile spread in tumors (increased potency), 2) intravenous stability and delivery to solid tumors, 3) therapeutic transgene-arming capacity, and 4) antidotes are available (to maximize safety). JX-594 is an engineered oncolytic virus designed to selectively destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells. JX-594 exploits a specific genetic feature in cancer cells to become activated and lyse the cells, including the EGFR-ras signaling pathway, the cell cycle activation and the loss of cellular interferon defenses. JX-594 is a Wyeth vaccinia virus with a disruption of the viral thymidine kinase (tk) gene and expression of the immunostimulatory cytokine, GM-CSF (granulocyte macrophage colony-stimulating factor).